Drug intelligence / Profile preview

SHR-4506

Development stage: Phase 1
Lead developer: Suzhou Suncadia Biopharmaceutical
Administration: Intravenous

Overview

SHR-4506 is a **class 1 therapeutic biological product** developed for the treatment of malignant tumors. It is being evaluated primarily for its safety and tolerability in patients with advanced malignant tumors, as well as its maximum tolerated dose[1][3][4][5][6][7][9][10]. Preclinical studies have suggested **good anti-tumor activity**, although precise details of the mechanism of action have not been disclosed in public sources. The drug is currently undergoing Phase 1 clinical trials and no similar drug has been approved for marketing worldwide[1][5]. The developer and primary manufacturer is Hengrui Pharmaceutical, through its subsidiary Suzhou Shengdia Biomedical[1].

Brand names: SHR-4506SHR4506SHR 4506
Other names: SHR-4506 injectionSHR4506 injectionSHR 4506 injection

Beyond the preview

Go deeper on SHR-4506.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SHR-4506.

Explore the full profile